Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study

Dumusc, Alexandre; Maldonado, Borbala Pazar; Benaïm, Charles; Zufferey, Pascal; Aubry‐Rozier, Bérengère; So, Alexander

doi:10.1016/j.jbspin.2020.105088

Cited by 18 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 33 In peripheral arthritis, Anakinra showed efficiency in decreasing pain and was well-tolerated. 46–49 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lumbar Spinal Involvement in Calcium Pyrophosphate Dihydrate Disease: A Systematic Literature Review

Tekaya¹,

Nacef²,

Bellil³

et al. 2022

IJGM

View full text Add to dashboard Cite

Background Calcium-pyrophosphate-dihydrate-disease (CPPD) is a crystal-induced arthropathy. The lumbar-spinal involvement is rare and often under-diagnosed. This study aimed to report the case of a lumbar spine CPPD involvement and to perform a systematic review of clinical, imaging features of lumbar involvement in CPPD patients, and treatments that have been implemented. Methods This systematic review was conducted in accordance with the Preferred-Reporting-Items-for-Systematic-Reviews and Meta-Analyses (PRISMA) guidelines. Results One hundred and sixty-seven articles met the search criteria using electronic databases searches. We retained 28 articles (20 case reports, 2 case series, 1 family survey, 4 retrospective studies, and 1 prospective study) involving a total of 62 patients. The age ranged between 39 and 89 years old. Among patients with lumbar spine CPPD, 32 were women. The duration of symptoms varied between one day and 8 years. The affection has been discovered during back pain in most cases. In 5 studies, the diagnosis was made on histological specimens of patients operated on for another pathology. X-ray showed calcifications in 2 cases. CT-scan detected calcium deposit in 7 cases. MRI showed lesions going from the increased signal of the disk, to calcified or not-cystic lesion of the facet joints, an intramedullary mass mimicking a schwannoma. Histological examination established the diagnosis of CPPD in 21 patients in all studies. Medical treatment included NSAIDs, Colchicine, Interleukin-1-receptor-antagonist, and antibiotics. Surgery was performed on 13 patients and allowed to establish the histological diagnosis. Conclusion In the case of inflammatory back pain in elderly subjects, without an infectious gateway, diagnosis of CPPD should be considered, especially for patients with a history of spinal surgery or degenerative radiography changes. CT scan is more sensitive than conventional radiographs. The discovertebral biopsy is the Gold-Standard and should be performed whenever the diagnosis was uncertain. Treatment includes the medical and surgical components.

show abstract

“… 33 In peripheral arthritis, Anakinra showed efficiency in decreasing pain and was well-tolerated. 46–49 …”

Section: Discussionmentioning

confidence: 99%

“…33 In peripheral arthritis, Anakinra showed efficiency in decreasing pain and was well-tolerated. [46][47][48][49] In our review, it was used in only one study, with a clinical and biological improvement. 28…”

mentioning

confidence: 99%

Lumbar Spinal Involvement in Calcium Pyrophosphate Dihydrate Disease: A Systematic Literature Review

Tekaya¹,

Nacef²,

Bellil³

et al. 2022

IJGM

View full text Add to dashboard Cite

show abstract

“…2020. Publication of results of the first clinical trials employing biologic drugs for the treatment of CPPD ( 49 , 50 ), including tocilizumab in symptomatic patients.…”

Section: Cppd Disease Timelinementioning

confidence: 99%

Calcium pyrophosphate deposition disease: historical overview and potential gaps

Pineda,

Sandoval,

Pérez-Neri

et al. 2024

Front. Med.

View full text Add to dashboard Cite

CPPD disease can affect patients’ quality of life through its various clinical presentations. This mini-review discusses the evolution of CPPD from its discovery to current knowledge of its pathogenesis, genetic associations, diagnostics, and treatment options. Despite extensive research, the exact mechanisms of CPPD are not well understood, and there is a notable lack of knowledge about psychosocial impacts and patient experiences. This study aims to present a CPPD Disease Timeline identifying gaps in current knowledge and potential directions for future research. These findings contribute to a broader understanding of CPPD disease and emphasize the importance of continued research and innovation in this field.

show abstract

“…Единственное на сегодняшний день маленькое рандомизированное контролируемое двойное слепое пилотное исследование, включившее 15 пациентов, 8 из которых получали анакинру в дозе 100 мг/сут., а остальные -преднизолон в дозе 30 мг/сут. на протяжении 3 дней, показало схожую эффективность в отношении уменьшения интенсивности боли, оценки по мнению врача и пациента, а также уровня СРБ сыворотки через 7 дней после завершения терапии [32]. Оценка эффекта препаратов через 24 и 72 часа позволила предположить, что анакинру, по-видимому, отличает более быстрое начало действия.…”

Section: таблица 2 динамика показателей воспалительной активности и о...unclassified

The use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature review

Елисеев¹,

Cheremushkina²,

Насонов

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Calcium pyrophosphate crystal deposition disease (CPPD) is a disease caused by the deposition of calcium pyrophosphate crystals, mainly in the articular cartilage, and often manifests as severe acute or chronic arthritis. Therapy given in such cases with non-steroidal anti-inflammatory drugs, colchicine, methotrexate and glucocorticoids is often effective. In these cases, the possibility of prescribing biological drugs, primarily interleukin 1 (IL-1) inhibitors, is being considered. The article analyzes the experience of using Anakinra, an IL-1 receptor antagonist, registered in the Russian Federation in 2021, in 5 patients with persistent arthritis in CPPD. The article also presents an analysis of data from key studies on the use of the drug in patients with CPPD.

show abstract

Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study

Cited by 18 publications

References 8 publications

Lumbar Spinal Involvement in Calcium Pyrophosphate Dihydrate Disease: A Systematic Literature Review

Lumbar Spinal Involvement in Calcium Pyrophosphate Dihydrate Disease: A Systematic Literature Review

Calcium pyrophosphate deposition disease: historical overview and potential gaps

The use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature review

Contact Info

Product

Resources

About